

Investor Conference 2021



科妍生物科技股份有限公司
SciVision Biotech Inc.

Dr. Chun Chang Chen
Project Manager | R&D Dept.

Disclaimer

This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control.

The forward-looking statements in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

Outline

- 1. Company & Product & Technology Overview**
- 2. Business Operation**

About SciVision Biotech Inc.



- Established in 2001
- Listed on TSE in 2013 (Code: 1786)
- **Professional high-class, pharmaceutical-grade Hyaluronic Acid medical device production**
- Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan
- Follow to GMP, ISO 13485, US FDA and PIC/s GMP standards
- Produces at least 12 million syringes of medical device annually




SCIVISION
BIOTECH INC.

Core Technologies

(Crosslinked Hyaluronic Acid Platform, CHAP[®])



Absorbable adhesion barrier




Single-injection viscosupplement



Dermal filler



Other new application category products



International Partnership



Listed Core Products

Applied field	Items	Global market value in 2020	CAGR
Facial Aesthetics	Dermal Filler	1.8 billion	9.0 %
Geriatrics Care	Synovial Fluid Supplement	2.3 billion	6.1 %
Surgery	Absorbable Adhesion Barrier	3.3 billion	8.9 %

Source:

1. Facial Aesthetics (Botulinum Toxin, Dermal Fillers), GlobalData
2. Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | 2019 , DRG
3. ANTI-ADHESION PRODUCTS 2012, Global Industry Analysts, Inc.

Dermal Filler

Monophasic Fillers (Smooth gel type)



Product advantages

- ✓ High safety performance
- ✓ Smooth and natural
- ✓ Easy operation


Biphasic Fillers (Particle type)



Product advantages

- ✓ High safety performance
- ✓ Strong structural support
- ✓ Shift resistance
- ✓ Excellent viscoelasticity
- ✓ Sufficient active ingredients
- ✓ Good resistance to degradation

Clinical Trials and Publications



1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2016 Jan 06(01):1-8.
2. Use of High-Resolution Ultrasound (HRU) in the Assessment of Deep Injections of CHAP-Hyaluronic Acid (CHAP-HA) Fillers for Midface Lift. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2018 Jan 08(03):126-132.
3. Dual-Plane Injection Technique With Microscale Tumescent Solution for Asian Rhinoplasty. *Dermatol Surg*. 2021 Jul 1;47(7):1015-1016.
4. CHAP-hyaluronic acid (CHAP-HA) filler as an optimal candidate for forehead filler augmentation using a 3-point injection technique. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2021 Jan 11(02):76-83.

Product injected around the eye was safe and effective, with high usage satisfaction



Figure 5. Before (upper) and immediately after (lower) single point deep injection of HA filler (1ml on each side) for cheek augmentation using 27 G sharp needle. Satisfactory results were noted with minimal bruising. Left: Case 2, Right: Case 7.

Product has good tissue compatibility






Figure 5. High-resolution ultrasound imaging immediately after HA injection (a, d, g, j), at 2-Week (b, e, h, k) and 4-week (c, f, i, l) follow up. Hydration of the HA would occur (arrows), and the ha would appear to be more heterogenous and hyperechoic (arrowheads) and may become completely unidentifiable with the surrounding tissues in the 4th week follow up (i, j).

Develop injection guidelines for high-risk areas





Guidelines for forehead augmentation




Listed Core Products

Applied field	Items	Global market value in 2020	CAGR
Facial Aesthetics	Dermal Filler	1.8 billion	9.0 %
Geriatrics Care	Synovial Fluid Supplement	2.3 billion	6.1 %
Surgery	Absorbable Adhesion Barrier	3.3 billion	8.9 %

Synovial Fluid Supplement


Product category	Treatment description	Global CAGR of treatments	Products
1-injection regimen (Long-acting)	Effect could be lasted for more than half a year with administrating 1 syringe.	10.2%	 <p data-bbox="1143 696 1518 768">1 syringe per year Super Long-Acting Type</p> <p data-bbox="1591 696 1854 768">Anti-free Radical Protection Type</p>
3-injection regimen	Effect could be lasted for half a year with administrating 3 syringes continuously, 1 syringe per week.	5.9%	 <p data-bbox="1232 996 1792 1039">Best-selling products in Taiwan</p>
5-injection regimen	Effect could be lasted for half a year with administrating 5 syringes continuously, 1 syringe per week.	5.5%	

Clinical Trials and Publications




1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. *J Bone Joint Surg Am.* 2011 Sep 21;93(18):1720-6.
2. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. *Exp Gerontol.* 2014 Apr;52:30-5.
3. Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. *J Bone Joint Surg Am.* 2017 Mar 15;99(6):462-471.
4. Origin and Efficacy of Hyaluronan Injections in Knee Osteoarthritis: Randomized, Double-Blind Trial. *Med Sci Monit.* 2018 Jul 9;24:4728-4737.
5. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis. *J Back Musculoskelet Rehabil.* 2018;31(4):709-718.
6. Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study. *BMC Musculoskelet Disord.* 2021 Jun 23;22(1):572.
7. Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. *Sci Rep.* 2021 Jan 8;11(1):140.

The pain relief effect is better than Sanofi's one-injection product.



The thickness of the quadriceps and cartilage improved significantly at 3 and 6 months after surgery.



The effect can be maintained for more than one year, with high satisfaction.

Table 3 Patient satisfaction in time interval

Time	CHAP-HA (N = 71)	Linear-HA (N = 69)	P value
4th week	66.4 ± 22.4	68.4 ± 24.7	0.622
12th week	73.2 ± 23.4	71.1 ± 25.2	0.601
26th week	73.4 ± 22.7	63.5 ± 26.5	< 0.018 [‡]
39th week	72.3 ± 22.4	52.1 ± 23.2	< 0.001 [‡]
52th week	61.7 ± 22.0	37.5 ± 23.1	< 0.001 [‡]

[‡] indicates a significant difference between groups ($P < 0.05$)

Listed Core Products

Applied field	Items	Global market value in 2020	CAGR
Facial Aesthetics	Dermal Filler	1.8 billion	9.0 %
Geriatrics Care	Synovial Fluid Supplement	2.3 billion	6.1 %
Surgery	Absorbable Adhesion Barrier	3.3 billion	8.9 %

Absorbable Adhesion Barrier

For gynecological pelvic surgery



Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance


For ligament, peripheral nerve, joint surgery



Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance
- ✓ Long effective protection time


Clinical Trials and Publications



1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. *J Appl Biomater Funct Mater*. Jan-Dec 2021;19.
2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. *Life*. 2020 May 15;10(5):67.
3. Efficacy of Applying Hyaluronic Acid Gels in the Primary Prevention of Intrauterine Adhesion after Hysteroscopic Myomectomy: A Meta-Analysis of Randomized Controlled Trials. *Life*. 2020 Nov 15;10(11):285.

Product could effectively avoid or slow down the occurrence of postoperative adhesions.

Product could effectively avoid or slow down the occurrence of postoperative adhesions and was significantly better than competing products.



	CHA-P Gel (n = 24)	CHA Gel (n = 23)	No (n = 23)	p-Value
Intrauterine Adhesion				
No	22 (91.7%) ^a	19 (82.6%) ^a	14 (60.9%)	0.031
Yes	2 (8.3%) ^a	4 (17.4%) ^a	9 (39.1%)	
Modified AFS Stage				
0	22 (91.7%) ^b	19 (82.6%) ^b	14 (60.9%)	0.014
I (mild)	2 (8.3%) ^b	3 (13.0%) ^b	1 (4.3%)	
II (moderate)	0 ^b	1 (4.3%) ^b	4 (17.4%)	
III (severe)	0 ^b	0 ^b	4 (17.4%)	

The data are presented as number (percentage). CHA-P (PROTAHERE absorbable adhesion barrier[®], SciVision Biotech Inc., Kaohsiung, Taiwan); CHA gel (Hyalobarrier[®] gel, Baxter, Pisa, Italy). No: no anti-adhesive agent gel treatment. AFS: American Fertility Society. ^a and ^b: The comparison between the CHA-P gel and CHA gel (^a: p-value = 0.352, ^b: p-value = 0.497).

Outline

1. Company & Product & Technology Overview

2. Business Operation


Profit & Loss-Consolidated

Unit:NT thousand dollars
(except for EPS)

	H1, ' 21 (Reviewed)		H1, ' 20 (Reviewed)		Annual growth rate
Revenue	238,033	100%	213,994	100%	11.2%
Cost of Goods Sold	(72,918)	-31%	(61,433)	-29%	18.7%
Gross Profit	165,115	69%	152,561	71%	8.2%
Operating Expense	(100,765)	-42%	(88,098)	-41%	14.4%
Operating Income	64,350	27%	64,463	30%	-0.2%
Non-operating Income, Net	(5,177)	-2%	3,872	2%	-233.7%
Income before Tax	59,173	25%	68,335	32%	-13.4%
Net Income	56,269	24%	58,704	27%	-4.1%
EPS(NT\$)	0.92		0.96		


Domestic and International Sales Ratio

2021 Jan.~Jun. & 2020 Jan.~Jun.



Product Portfolio Sales Ratio

2021 Jan.~Jun. & 2020 Jan.~Jun.



Balance Sheet-Consolidated

Unit:NT thousand dollars


	2021/6/30 (Reviewed)		2020/6/30 (Reviewed)	
Cash and Cash Equivalents	616,055	27%	293,159	15%
Accounts Receivable	67,496	3%	55,371	3%
Inventories	52,797	2%	31,106	2%
Current Financial Assets at Fair Value through Profit or Loss	-	0%	53,500	3%
Amortized Cost Financial Assets	99,927	4%	133,998	7%
Property, Plant & Equipment	1,283,340	56%	1,257,559	65%
Other Current/Non-Current Assets	160,944	7%	98,546	5%
Total Assets	2,280,559	100%	1,923,239	100%
Current Liabilities	421,933	18%	226,328	11%
Long-Term & Other Liabilities	398,194	17%	356,766	19%
Total Liabilities	820,127	36%	583,094	30%
Total Shareholders' Equities	1,460,432	64%	1,340,145	70%
Key Indices				
A/R Turnover (Days)	51.90		49.69	
Inventory Turnover (Days)	123.51		95.14	
Current Ratio(x)	205.56%		262.75%	
Net Profit Margin(%)	23.64%		27.43%	

Cash Flows-Consolidated


<i>Unit:NT thousand dollars</i>	H1, ' 21 (Reviewed)	H1, ' 20 (Reviewed)
From Operating Activities	70, 199	67, 689
Profit before tax	59, 173	68, 335
Depreciation & Amortisation	19, 730	6, 873
Net change in working capital	(8, 704)	(7, 519)
From Investing Activities	(150, 905)	(104, 971)
amortised cost	(84, 175)	(38, 391)
through Profit or Loss	0	(50, 000)
Capital expenditure	(15, 264)	(17, 780)
Net change in Investing item	(51, 466)	1, 200
From Financing Activities	299, 397	(606)
Short-term loans	0	0
Long-term loans	300, 000	0
Net change in Fincncing item	(603)	(606)
Net Change in Cash	218, 691	(37, 888)
Beginning Balance	397, 364	331, 047
Ending Balance	616, 055	293, 159
Free Cash Flow	54, 935	49, 909

HEALTHY CASHFLOW AND EXPANDING PROFIT


Revenue




Gross and Operating Margin



Net Profit



Cash Generated From Operations Before Interest And Taxes



Our Vision



Science Creates Better Visions